Helen M Ameis1, Astrid Drenckhan2, Morton Freytag2, Jakob R Izbicki2, Claudiu T Supuran3, Konrad Reinshagen1, Stefan Holland-Cunz4, Stephanie J Gros5,6. 1. Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf/Altona Children's Hospital, Hamburg, Germany. 2. Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. 3. Department Neurofarba, Sezione di Scienze farmaceutiche, University of Florence, Florence, Italy. 4. Department of Pediatric Surgery, University Children's Hospital of Basel, Spitalstrasse 33, 4031, Basel, Switzerland. 5. Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. stephanie.gros@ukbb.ch. 6. Department of Pediatric Surgery, University Children's Hospital of Basel, Spitalstrasse 33, 4031, Basel, Switzerland. stephanie.gros@ukbb.ch.
Abstract
PURPOSE: Several oxygen-dependent factors, e.g., CAIX (carbonic anhydrase IX) or phosphoglycerate kinase 1 (PGK1) interacting with the CXCR4/SDF1 axis (chemokine receptor 4/stromal cell derived factor 1) have been shown to be involved in processes of tumour pathology including tumourigenicity, tumour cell dissemination and poor survival in several solid tumour entities. The aim of the current study was to evaluate the influence of the hypoxia-inducible factors CAIX and PGK1 on progression of neuroblastoma and to evaluate the clinical relevance of possible therapeutic approaches. METHODS: Expression of hypoxia-dependent factors PGK1 and CAIX was examined in neuroblastoma specimen, was correlated with clinical parameters, and was studied in neuroblastoma cells. The impact of these hypoxic factors was evaluated by proliferation assays under targeted therapy. RESULTS: Expression of hypoxia-dependent factors was found in 50 % of neuroblastoma specimen. In neuroblastoma cells, CAIX and PGK1 expression is up regulated under hypoxia and correlates with response to targeted anti-proliferative treatment. The negative impact on survival, although significant for both CAIX and PGk1, appears to be stronger for CAIX. CONCLUSIONS: Our results show that the hypoxic factors in the tumour`s microenvironment further the progression of tumour disease. This strengthens the perspectives for additive novel therapeutic approaches targeting hypoxia-dependent factors in this childhood disease.
PURPOSE: Several oxygen-dependent factors, e.g., CAIX (carbonic anhydrase IX) or phosphoglycerate kinase 1 (PGK1) interacting with the CXCR4/SDF1 axis (chemokine receptor 4/stromal cell derived factor 1) have been shown to be involved in processes of tumour pathology including tumourigenicity, tumour cell dissemination and poor survival in several solid tumour entities. The aim of the current study was to evaluate the influence of the hypoxia-inducible factors CAIX and PGK1 on progression of neuroblastoma and to evaluate the clinical relevance of possible therapeutic approaches. METHODS: Expression of hypoxia-dependent factors PGK1 and CAIX was examined in neuroblastoma specimen, was correlated with clinical parameters, and was studied in neuroblastoma cells. The impact of these hypoxic factors was evaluated by proliferation assays under targeted therapy. RESULTS: Expression of hypoxia-dependent factors was found in 50 % of neuroblastoma specimen. In neuroblastoma cells, CAIX and PGK1 expression is up regulated under hypoxia and correlates with response to targeted anti-proliferative treatment. The negative impact on survival, although significant for both CAIX and PGk1, appears to be stronger for CAIX. CONCLUSIONS: Our results show that the hypoxic factors in the tumour`s microenvironment further the progression of tumour disease. This strengthens the perspectives for additive novel therapeutic approaches targeting hypoxia-dependent factors in this childhood disease.
Authors: Patricio E Morgan; Silvia Pastoreková; Alan K Stuart-Tilley; Seth L Alper; Joseph R Casey Journal: Am J Physiol Cell Physiol Date: 2007-07-25 Impact factor: 4.249
Authors: C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701
Authors: P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: Nicholas C Denko; Lucrezia A Fontana; Karen M Hudson; Patrick D Sutphin; Soumya Raychaudhuri; Russ Altman; Amato J Giaccia Journal: Oncogene Date: 2003-09-01 Impact factor: 9.867
Authors: Helen M Ameis; Astrid Drenckhan; Katharina von Loga; Gabriele Escherich; Katharina Wenke; Jakob R Izbicki; Konrad Reinshagen; Stephanie J Gros Journal: PLoS One Date: 2013-12-20 Impact factor: 3.240
Authors: Silvia A Teixeira; Mariano S Viapiano; Augusto F Andrade; Mohan S Nandhu; Julia A Pezuk; Lucas T Bidinotto; Veridiana K Suazo; Luciano Neder; Carlos G Carlotti; Aline P Becker; Luiz Gonzaga Tone; Carlos A Scrideli Journal: Mol Neurobiol Date: 2021-06-03 Impact factor: 5.590
Authors: Carolina Bernauer; Y K Stella Man; Julia C Chisholm; Elise Y Lepicard; Simon P Robinson; Janet M Shipley Journal: Br J Cancer Date: 2020-10-27 Impact factor: 7.640
Authors: Zihe Huo; Remo Bilang; Claudiu T Supuran; Nicolas von der Weid; Elisabeth Bruder; Stefan Holland-Cunz; Ivan Martin; Manuele G Muraro; Stephanie J Gros Journal: Int J Mol Sci Date: 2022-03-14 Impact factor: 5.923